The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Model-informed COVID-19 vaccine prioritization strategies by age and serostatus
Open accessPublished version of a preprint
Abstract
Limited initial supply of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine raises the question of how to prioritize available doses. We used a mathematical model to compare five age-stratified prioritization strategies. A highly effective transmission-blocking vaccine prioritized to adults ages 20 to 49 years minimized cumulative incidence, but mortality and years of life lost were minimized in most scenarios when the vaccine was prioritized to adults greater than 60 years old. Use of individual-level serological tests to redirect doses to seronegative individuals improved the marginal impact of each dose while potentially reducing existing inequities in COVID-19 impact. Although maximum impact prioritization strategies were broadly consistent across countries, transmission rates, vaccination rollout speeds, and estimates of naturally acquired immunity, this framework can be used to compare impacts of prioritization strategies across contexts.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Impacts of vaccine prioritization strategies on mortality and infections. (A) Distribution of vaccines for five prioritization strategies: under 20 years, adults 20 to 49 years, adults 20+ years, adults 60+ years, and all ages. (B, C, F, and G) Example simulation curves show [(B) and (C)] percentage of the total population infected over time and [(F) and (G)] cumulative mortality for no vaccines (gray dashed lines) and for five different prioritization strategies [colored lines matching (A)], with [(B) and (F)] 10% and [(C) and (G)] 30% vaccine supply. (D, E, H, and I) Summary curves show percent reductions in [(D) and (E)] infections and [(H) and (I)] deaths in comparison to an unmitigated outbreak for vaccine supplies between 1 and 50% after 365 days of simulation. Squares and diamonds show how the outputs from single simulations [(F) and (G)] correspond to points in summary curves (H). Gray shading indicates the period during which vaccine is being rolled out at 0.2% of total population per day. Black dots indicate break points at which prioritized demographic groups have been 70% vaccinated, after which vaccines are distributed without prioritization. These simulations assume contact patterns and demographics of the United States (38, 53) and an all-or-nothing, transmission-blocking vaccine with 90% vaccine efficacy and R0 = 1.5 (scenario 2) and R0 = 1.15 (scenario 1).](https://figures.cochat.ai/paper-figures/040af1c419fe4105805e757ba6eecdfa/model-informed-covid-19-vaccine-prioritization-strategies-by-age-and-serostatus-figure-1.jpg)
![Fig. 2 Mortality-minimizing vaccine prioritization strategies across reproductive numbers R0 and countries. (A to E) Heatmaps show the prioritization strategies that result in maximum reduction of mortality for varying values of [(A) and (B)] the basic reproductive number R0 and [(C), (D), and (E)] across nine countries, for vaccine supplies between 1 and 50% of the total population, for an all-or-nothing and transmission-blocking vaccine, 90% vaccine efficacy. [(A) and (B)] Contact patterns and demographics of the United States (38, 53). [(C), (D), and (E)] Contact patterns and demographics of POL, Poland; ZAF, South Africa; CHN, China; BRA, Brazil; ZWE, Zimbabwe; ESP, Spain; IND, India; USA, United States of America; and BEL, Belgium, with R0 and rollout speeds as indicated.](https://figures.cochat.ai/paper-figures/3232e6d2c98d4491b422e996e35f7beb/model-informed-covid-19-vaccine-prioritization-strategies-by-age-and-serostatus-figure-2.jpg)
![Fig. 3 Effects of age-dependent vaccine efficacy on the impacts of prioritization strategies. (A) Diagram of hypothetical age-dependent vaccine efficacy shows decrease from 90% baseline efficacy to 50% efficacy among individuals aged 80+ years, beginning at age 60 (dashed line). (B and C) Percent reduction in deaths in comparison with an unmitigated outbreak for transmission-blocking all-or-nothing vaccines with either constant 90% efficacy for all age groups (solid lines) or age-dependent efficacy shown in (A) (dashed lines), covering scenario 1 [0.2% rollout per day, R0 = 1.15; (B)] and scenario 2 [0.2% rollout per day, R0 = 1.5 (C)]. Black dots indicate break points at which prioritized demographic groups have been 70% vaccinated, after which vaccines are distributed without prioritization. Shown are contact patterns and demographics of the United States (38, 53); all-or-nothing and transmission-blocking vaccine.](https://figures.cochat.ai/paper-figures/85e54e74290b4a1b82ec5b49b5f8d03f/model-informed-covid-19-vaccine-prioritization-strategies-by-age-and-serostatus-figure-3.jpg)
![Fig. 4 Effects of existing seropositivity on the impacts of prioritization strategies. (A to C) Percent reductions in (A) infections, (B) deaths, and (C) years of life lost (YLL) for prioritization strategies when existing age-stratified seroprevalence is incorporated [August 2020 estimates for New York City; mean seroprevalence 26.9% (28)]. Plots show reductions for scenario 2 (0.2% rollout per day, R0 = 1.5) when vaccines are given to all individuals (solid lines) or to only seronegatives (dashed lines), inclusive of 96% serotest sensitivity, 99% specificity (54), and approximately 3 months of seroreversion (supplementary materials, materials and methods) (29). Shown are U.S. contact patterns and demographics (38, 53), all-or-nothing and transmission-blocking vaccine with 90% vaccine efficacy. Lower and higher seroprevalence examples are provided in figs. S12 and S13, respectively.](https://figures.cochat.ai/paper-figures/4122f4138dc44271af1ce6fd7d40abb0/model-informed-covid-19-vaccine-prioritization-strategies-by-age-and-serostatus-figure-4.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Vaccination alone is not expected to be able to control the spread of the infection, and a carefully planned vaccination campaign25,26 needs to be coordinated with continued implementation of NPIs27 until sufficient coverage is reached to make the case fatality rate (CFR) similar to that of seasonal influenza.”
From Modeling vaccination rollouts, SARS-CoV-2 variants and the requirement for non-pharmaceutical interventions in Italy (2021) · cites this paper as [25]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection.
Dan, J. M., Mateus, J., Kato, Y., Hastie, K. M., Yu, E. D., Faliti, C. E., Grifoni, A., Ramirez, S. I., Haupt, S., Frazier, A., et al. (2021) · Science · doi:10.1126/science.abf4063 · Cited by 2,656
COVID-19 and Racial/Ethnic Disparities
Webb Hooper, M., Nápoles, A. M., & Pérez-Stable, E. J. (2020) · JAMA · doi:10.1001/jama.2020.8598 · Cited by 2,047 · cited 1×
“However, other factors correlate with disease outcomes, such as treatment and healthcare access and comorbidities, which may correlate with factors like rural vs urban location, socioeconomic status, sex ( 41, 42 ), and race and ethnicity ( 43 ), that are not accounted for in this study.”
Age-dependent effects in the transmission and control of COVID-19 epidemics
Davies, N. G., Klepac, P., Liu, Y., Prem, K., Jit, M., CMMID COVID-19 working group, Pearson, C. A. B., Quilty, B. J., Kucharski, A. J., Gibbs, H., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0962-9 · Cited by 1,759 · cited 1×
“Age-stratified susceptibility values were drawn from literature estimates ( 13 ).”
Sex differences in immune responses that underlie COVID-19 disease outcomes
Takahashi, T., Ellingson, M. K., Wong, P., Israelow, B., Lucas, C., Klein, J., Silva, J., Mao, T., Oh, J. E., Tokuyama, M., et al. (2020) · Nature · doi:10.1038/s41586-020-2700-3 · Cited by 1,459 · cited 1×
“However, other factors correlate with disease outcomes, such as treatment and healthcare access and comorbidities, which may correlate with factors like rural vs urban location, socioeconomic status, sex ( 41, 42 ), and race and ethnicity ( 43 ), that are not accounted for in this study.”
Why does COVID-19 disproportionately affect older people?
Mueller, A. L., McNamara, M. S., & Sinclair, D. A. (2020) · Aging · doi:10.18632/aging.103344 · Cited by 1,128 · cited 1×
“We evaluated the impact of vaccine prioritization strategies using an age-stratified SEIR model, because age has been shown to be an important correlate of susceptibility ( 12–14 ), seroprevalence ( 12,15 ), severity ( 16–18 ), and mortality ( 19,20 ).”
Changes in contact patterns shape the dynamics of the COVID-19 outbreak in China
Zhang, J., Litvinova, M., Liang, Y., Wang, Y., Wang, W., Zhao, S., Wu, Q., Merler, S., Viboud, C., Vespignani, A., et al. (2020) · Science · doi:10.1126/science.abb8001 · Cited by 1,107 · cited 1×
“We evaluated the impact of vaccine prioritization strategies using an age-stratified SEIR model, because age has been shown to be an important correlate of susceptibility ( 12–14 ), seroprevalence ( 12,15 ), severity ( 16–18 ), and mortality ( 19,20 ).”
The Efficacy of Influenza Vaccine in Elderly Persons: A Meta-Analysis and Review of the Literature
Gross, P. A., Hermogenes, A. W., Sacks, H. S., Lau, J., & Levandowski, R. A. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-123-7-199510010-00008 · Cited by 1,100 · cited 1×
“COVID-19 vaccines may not be equally effective across age groups in preventing infection or transmission, a phenomenon known to affect influenza vaccines ( 23–26 ).”
Estimating the burden of SARS-CoV-2 in France
Salje, H., Tran Kiem, C., Lefrancq, N., Courtejoie, N., Bosetti, P., Paireau, J., Andronico, A., Hozé, N., Richet, J., Dubost, C.-L., et al. (2020) · Science · doi:10.1126/science.abc3517 · Cited by 1,038
Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers
Lumley, S. F., O’Donnell, D., Stoesser, N. E., Matthews, P. C., Howarth, A., Hatch, S. B., Marsden, B. D., Cox, S., James, T., Warren, F., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2034545 · Cited by 940 · cited 2×
“Serostatus itself is an imperfect indicator of protection, and the relationship of prior infection, serostatus, and protection may change over time (10, 29,32,33).”
Govaert, T. M. E. (1994) · JAMA · doi:10.1001/jama.1994.03520210045030 · Cited by 867
Badr, H. S., Du, H., Marshall, M., Dong, E., Squire, M. M., & Gardner, L. M. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30553-3 · Cited by 851
Levin, A. T., Hanage, W. P., Owusu-Boaitey, N., Cochran, K. B., Walsh, S. P., & Meyerowitz-Katz, G. (2020) · European Journal of Epidemiology · doi:10.1007/s10654-020-00698-1 · Cited by 844 · cited 8×
“This recommendation is robust because of the dramatic differences in IFR by age.”
InfluentialQuantifying the impact of physical distance measures on the transmission of COVID-19 in the UK
CMMID COVID-19 working group, Jarvis, C. I., Van Zandvoort, K., Gimma, A., Prem, K., Klepac, P., Rubin, G. J., & Edmunds, W. J. (2020) · BMC Medicine · doi:10.1186/s12916-020-01597-8 · Cited by 720 · cited 1×
“We used pre-pandemic contact matrices (21), reflecting the goal of a return to pre-pandemic routines once a vaccine is available, but more recent estimates of age-stratified contact rates could be valuable in modeling mid-pandemic scenarios (36, 37).”
Optimizing Influenza Vaccine Distribution
Medlock, J., & Galvani, A. P. (2009) · Science · doi:10.1126/science.1175570 · Cited by 437
Association between age and clinical characteristics and outcomes of COVID-19
Liu, Y., Mao, B., Liang, S., Yang, J.-W., Lu, H.-W., Chai, Y.-H., Wang, L., Zhang, L., Li, Q.-H., Zhao, L., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.01112-2020 · Cited by 427
Vaccine optimization for COVID-19: Who to vaccinate first?
Matrajt, L., Eaton, J., Leung, T., & Brown, E. R. (2021) · Science Advances · doi:10.1126/sciadv.abf1374 · Cited by 419
Vaccine optimization for COVID-19, who to vaccinate first?Preprint
Matrajt, L., Eaton, J., Leung, T., et al. (2020) · medRxiv · doi:10.1101/2020.08.14.20175257 · Cited by 412 · cited 3×
“However, for leaky vaccines, prioritization shifted toward children and teenagers for vaccine efficacy of 50%, in line with prior work ( 7 ).”
InfluentialFace mask use in the general population and optimal resource allocation during the COVID-19 pandemic
Worby, C. J., & Chang, H.-H. (2020) · Nature Communications · doi:10.1038/s41467-020-17922-x · Cited by 379 · cited 1×
“The problem of vaccine prioritization also parallels the more general problem of optimal resource allocation to reduce transmission, e.g. with masks ( 11 ).”
An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment
GeurtsvanKessel, C. H., Okba, N. M. A., Igloi, Z., Bogers, S., Embregts, C. W. E., Laksono, B. M., Leijten, L., Rokx, C., Rijnders, B., Rahamat-Langendoen, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17317-y · Cited by 361 · cited 3×
“5) when vaccines are given to all individuals (solid lines) or to only seronegatives (dashed lines), inclusive of 96% serotest sensitivity, 99% specificity (35), and approximately three months of seroreversion (32) (see Methods).”
On the Effect of Age on the Transmission of SARS-CoV-2 in Households, Schools, and the Community
Goldstein, E., Lipsitch, M., & Cevik, M. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa691 · Cited by 355
Self-citationFramework for Equitable Allocation of COVID-19 Vaccine
Committee on Equitable Allocation of Vaccine for the Novel Coronavirus, Board on Health Sciences Policy, Board on Population Health and Public Health Practice, Division, H. A. M., & National Academies of Sciences, E. (2020) · National Academies Press eBooks · doi:10.17226/25917 · Cited by 337
Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020
Bajema, K. L., Wiegand, R. E., Cuffe, K., Patel, S. V., Iachan, R., Lim, T., Lee, A., Moyse, D., Havers, F. P., Harding, L., et al. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.7976 · Cited by 276 · cited 2×
“To incorporate existing seroprevalence and compare areas with differing naturally-acquired immunity, we used data and seroprevalence estimates from Connecticut [low seroprevalence; ( 28 )] and New York City S2, where sp = 1 , se = 0 .”
InfluentialPrem, K., Zandvoort, K. V., Klepac, P., Eggo, R. M., Davies, N. G., Centre for the Mathematical Modelling of Infectious Diseases COVID-19 Working Group, Cook, A. R., & Jit, M. (2021) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1009098 · Cited by 268 · cited 11×
“These simulations assume contact patterns and demographics of the United States (22, 23) and an all-or-nothing, transmission-blocking vaccine with 90% vaccine efficacy and R0 = 1.”
InfluentialPopulation-wide benefits of routine vaccination of children against influenza
Weycker, D., Edelsberg, J., Elizabeth Halloran, M., Longini, I. M., Nizam, A., Ciuryla, V., & Oster, G. (2005) · Vaccine · doi:10.1016/j.vaccine.2004.08.044 · Cited by 266 · cited 2×
“The strategies prioritized vaccines to (1) children and teenagers, (2) adults between ages 20 and 49 years, (3) adults 20 years or older, (4) adults 60 years or older, and (5) all individuals (Figure 1A).”
Understanding COVID-19 vaccine efficacy
Lipsitch, M., & Dean, N. E. (2020) · Science · doi:10.1126/science.abe5938 · Cited by 228
Self-citationDynamic prioritization of COVID-19 vaccines when social distancing is limited for essential workers
Buckner, J. H., Chowell, G., & Springborn, M. R. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2025786118 · Cited by 216 · cited 1×
“Prioritization of transmission-blocking vaccines can also be dynamically updated based on the current state of the epidemic, shifting prioritization to avoid decreasing marginal returns (9).”
COVID-19 in Prisons and Jails in the United States
Hawks, L., Woolhandler, S., & McCormick, D. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.1856 · Cited by 204
Ward, H., Cooke, G. S., Atchison, C., Whitaker, M., Elliott, J., Moshe, M., Brown, J. C., Flower, B., Daunt, A., Ainslie, K., et al. (2021) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2021.100098 · Cited by 197
Immune History and Influenza Vaccine Effectiveness
Lewnard, J. A., & Cobey, S. (2018) · Vaccines · doi:10.3390/vaccines6020028 · Cited by 196 · cited 1×
“COVID-19 vaccines may not be equally effective across age groups in preventing infection or transmission, a phenomenon known to affect influenza vaccines ( 23–26 ).”
Self-citationSandmann, F. G., Davies, N. G., Vassall, A., Edmunds, W. J., Jit, M., Sun, F. Y., Villabona-Arenas, C. J., Nightingale, E. S., Showering, A., Knight, G. M., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00079-7 · Cited by 176 · cited 5×
“These efforts to prioritize and optimize doses complement other work showing that, under a variety of scenarios of vaccine efficacy and durability of immunity, the economic and health benefits of COVID-19 vaccines will be large in the short and medium terms (10).”
InfluentialImpaired Cytotoxic CD8 + T Cell Response in Elderly COVID-19 Patients
Westmeier, J., Paniskaki, K., Karakoese, Z., Werner, T., Sutter, K., Dolff, S., Overbeck, M., Limmer, A., Liu, J., Zheng, X., et al. (2020) · mBio · doi:10.1128/mbio.02243-20 · Cited by 170
Sex differences in SARS-CoV-2 infection rates and the potential link to prostate cancer
Chakravarty, D., Nair, S. S., Hammouda, N., Ratnani, P., Gharib, Y., Wagaskar, V. G., Mohamed, N., Lundon, D., Dovey, Z. S., Kyprianou, N., et al. (2020) · Communications Biology · doi:10.1038/s42003-020-1088-9 · Cited by 160 · cited 1×
“However, other factors correlate with disease outcomes, such as treatment and healthcare access and comorbidities, which may correlate with factors like rural vs urban location, socioeconomic status, sex (46, 47), and race and ethnicity (48), that are not accounted for in this study.”
Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adultsPreprint
Ward, H., Cooke, G., Atchison, C. J., et al. (2020) · medRxiv · doi:10.1101/2020.10.26.20219725 · Cited by 154 · cited 7×
“In scenarios where vaccination was targeted only at seronegative individuals, simulations were conducted with sensitivity 70% and specificity 99%, incorporating the performance of a hypothetical Euroimmun IgG test (35) and a 25% reduction in sensitivity due to seroreversion (32).”
InfluentialLee, J. K. H., Lam, G., Shin, T., Kim, J., Krishnan, A., Greenberg, D. P., & Chit, A. (2018) · Expert Review of Vaccines · doi:10.1080/14760584.2018.1471989 · Cited by 149
Immunological memory to SARS-CoV-2 assessed for up to eight months after infectionPreprint
Dan, J., Mateus, J., Kato, Y., Hastie, K., Yu, E., Faliti, C. E., Grifoni, A., Ramirez, S., Haupt, S., Frazier, A., et al. (2020) · bioRxiv · doi:10.1101/2020.11.15.383323 · Cited by 147
A Comparative Analysis of Influenza Vaccination Programs
Bansal, S., Pourbohloul, B., & Ancel, L. W. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030387 · Cited by 137 · cited 1×
“Model-based investigations of the tradeoffs between these strategies for influenza vaccination have led to recommendations that children be vaccinated due to their critical role in transmission (4, 5), and have shown that direct protection is superior when reproduction numbers are high but indirect protection is super…”
Predicted COVID-19 fatality rates based on age, sex, comorbidities and health system capacity
Ghisolfi, S., Almås, I., Sandefur, J., von Carnap, T., Heitner, J., & Bold, T. (2020) · BMJ Global Health · doi:10.1136/bmjgh-2020-003094 · Cited by 123
The early landscape of coronavirus disease 2019 vaccine development in the UK and rest of the world
Sharpe, H., Gilbride, C., Allen, E. R., Belij‐Rammerstorfer, S., Bissett, C., Ewer, K., & Lambe, T. (2020) · Immunology · doi:10.1111/imm.13222 · Cited by 109
Backer, J. A., Mollema, L., Vos, E. R. A., Klinkenberg, D., van der Klis, F. R. M., de Melker, H. E., van den Hof, S., & Wallinga, J. (2021) · Eurosurveillance · doi:10.2807/1560-7917.es.2021.26.8.2000994 · Cited by 109
If a coronavirus vaccine arrives, can the world make enough?
Khamsi, R. (2020) · Nature · doi:10.1038/d41586-020-01063-8 · Cited by 102 · cited 3×
“The strategies prioritized vaccines to (1) children and teenagers, (2) adults between ages 20 and 49 years, (3) adults 20 years or older, (4) adults 60 years or older, and (5) all individuals (Figure 1A).”
Larremore, D. B., Fosdick, B. K., Bubar, K. M., Zhang, S., Kissler, S. M., Metcalf, C. J. E., Buckee, C. O., & Grad, Y. H. (2021) · eLife · doi:10.7554/elife.64206 · Cited by 95 · cited 2×
“We demonstrated that there is value in pairing individual-level serological tests with vaccination, even when accounting for the uncertainties in seroprevalence estimates ( 29 ).”
Self-citationDose‐Optimal Vaccine Allocation over Multiple Populations
Westerink-Duijzer, L. E., van Jaarsveld, W. L., Wallinga, J., & Dekker, R. (2017) · Production and Operations Management · doi:10.1111/poms.12788 · Cited by 93 · cited 1×
“First, our evaluation strategy focuses on a single country at a time [rather than on between-population allocation (40)], and considers variation in disease severity only by age.”
Herzog, S. A., Bie, J. D., Abrams, S., Wouters, I., Ekinci, E., Patteet, L., Coppens, A., Spiegeleer, S. D., Beutels, P., Damme, P. V., et al. (2022) · Eurosurveillance · doi:10.2807/1560-7917.es.2022.27.9.2100419 · Cited by 91
Herzog, S. A., Bie, J. D., Abrams, S., et al. (2020) · medRxiv · doi:10.1101/2020.06.08.20125179 · Cited by 85 · cited 1×
“Evaluation of vaccine prioritization strategies We evaluated the impact of vaccine prioritization strategies using an age-stratified SEIR model, because age has been shown to be an important correlate of susceptibility (12–14), seroprevalence (12,15), severity (16–18), and mortality (19, 20).”
Vaccine Effects on Heterogeneity in Susceptibility and Implications for Population Health Management
Langwig, K. E., Wargo, A. R., Jones, D. R., Viss, J. R., Rutan, B. J., Egan, N. A., Sá-Guimarães, P., Kim, M. S., Kurath, G., Gomes, M. G. M., et al. (2017) · mBio · doi:10.1128/mbio.00796-17 · Cited by 62 · cited 1×
“Because a vaccine is likely to have properties of both leaky and all-or-nothing models, empirical data on vaccine performance could help resolve this difference in model recommendations, although data are difficult to obtain in practice [see, e.g. ( 30,31 )].”
Self-citationPrem, K., van Zandvoort, K., Klepac, P., et al. (2020) · medRxiv · doi:10.1101/2020.07.22.20159772 · Cited by 62
Understanding heterogeneity to inform the public health response to COVID-19 in Canada
Mishra, S., Kwong, J. C., Chan, A. K., & Baral, S. D. (2020) · Canadian Medical Association Journal · doi:10.1503/cmaj.201112 · Cited by 50
Limitations of using mobile phone data to model COVID-19 transmission in the USA
Badr, H. S., & Gardner, L. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30861-6 · Cited by 48
Ellenberger, D. L., Otten, R. A., Li, B., Aidoo, M., Rodriguez, I., Sariol, C. A., Martínez, M. I., Monsour, M., Wyatt, L. S., Hudgens, M. G., et al. (2006) · Virology · doi:10.1016/j.virol.2006.04.005 · Cited by 47
Indirect benefits are a crucial consideration when evaluating SARS-CoV-2 vaccine candidates
Gallagher, M., Sieben, A. J., Nelson, K., Kraay, A. N. M., Orenstein, W. A., Lopman, B. A., Handel, A., & Koelle, K. (2020) · Nature Medicine · doi:10.1038/s41591-020-01172-x · Cited by 47
Sandmann, F., Davies, N. G., Vassall, A., et al. (2020) · medRxiv · doi:10.1101/2020.09.24.20200857 · Cited by 46
Impaired cytotoxic CD8+ T cell response in elderly COVID-19 patientsPreprint
Westmeier, J., Paniskaki, K., Karaköse, Z., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.08.21.262329 · Cited by 36
Backer, J. A., Mollema, L., Vos, R. A. E., et al. (2020) · medRxiv · doi:10.1101/2020.05.18.20101501 · Cited by 28 · cited 1×
“We used pre-pandemic contact matrices (21), reflecting the goal of a return to pre-pandemic routines once a vaccine is available, but more recent estimates of age-stratified contact rates could be valuable in modeling mid-pandemic scenarios (36, 37).”
Predicted COVID-19 fatality rates based on age, sex, comorbidities, and health system capacityPreprint
Ghisolfi, S., Almås, I., Sandefur, J., et al. (2020) · medRxiv · doi:10.1101/2020.06.05.20123489 · Cited by 26 · cited 1×
“In local contexts, these include age-structured seroprevalence and IFR, which vary by population ( 19, 20, 38 ).”
Considering indirect benefits is critical when evaluating SARS-CoV-2 vaccine candidatesPreprint
Gallagher, M., Sieben, A. J., Nelson, K., et al. (2020) · medRxiv · doi:10.1101/2020.08.07.20170456 · Cited by 18
The line is forming for a COVID-19 vaccine. Who should be at the front?
Cohen, J. (2020) · Science · doi:10.1126/science.abd5770 · Cited by 17
The line starts to form for a coronavirus vaccine
Cohen, J. (2020) · Science · doi:10.1126/science.369.6499.15 · Cited by 14
CDC vaccine committee may prioritize health care workers for COVID-19 vaccines
Jenco, M. (2021) · AAP News · Cited by 2
kbubar/vaccine_prioritization: Updated code for published paper
Kbubar (2020) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.4308794
Research works printed but not linked: 1
- K. E. Atkinson An Introduction to Numerical Analysis (Wiley 1989) chap. 2 pp. 56–58 second edn.
Cited by
Goel, R. R., Apostolidis, S. A., Painter, M. M., Mathew, D., Pattekar, A., Kuthuru, O., Gouma, S., Hicks, P., Meng, W., Rosenfeld, A. M., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abi6950 · Cited by 655
Vaccination and non-pharmaceutical interventions for COVID-19: a mathematical modelling study
Moore, S., Hill, E. M., Tildesley, M. J., Dyson, L., & Keeling, M. J. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00143-2 · Cited by 537
Age-dependent Immune Response to the Biontech/Pfizer BNT162b2 Coronavirus Disease 2019 Vaccination
Müller, L., Andrée, M., Moskorz, W., Drexler, I., Walotka, L., Grothmann, R., Ptok, J., Hillebrandt, J., Ritchie, A., Rabl, D., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab381 · Cited by 511
“A recent, thorough study using mathematical 86 modeling to investigate vaccine prioritization strategies supports the preferential 87 vaccination of the elderly [20].”
BackgroundThe changing epidemiology of SARS-CoV-2
Koelle, K., Martin, M. A., Antia, R., Lopman, B., & Dean, N. E. (2022) · Science · doi:10.1126/science.abm4915 · Cited by 295
Understanding COVID-19 vaccine efficacy
Lipsitch, M., & Dean, N. E. (2020) · Science · doi:10.1126/science.abe5938 · Cited by 228
Self-citation
Metadata
- Authors
- Bubar, K. M., Reinholt, K., Kissler, S. M., Lipsitch, M., Cobey, S., Grad, Y. H., & Larremore, D. B.
- Affiliations
- University of Colorado Boulder (US)
- Harvard University (US)
- University of Chicago (US)
- Corresponding author
- Bubar, Kate M.
- Larremore, Daniel B.
- ORCID
- Venue
- Science
- Published
- 2021-02-26
- Volume
- 371
- Issue
- 6532
- Pages
- 916-921
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC7963218
- OpenAlex
- W3123021790
- Cited by
- 775
- References
- 45
- Citations by year
- 2026: 32 · 2025: 56 · 2024: 87 · 2023: 109 · 2022: 222 · 2021: 261
- FWCI
- 65.62
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Science (publishedVersion, cc-by)
- medRxiv (acceptedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Knowledge@UChicago (University of Chicago) (submittedVersion, cc-by-nc-nd)
- PubMed Central (submittedVersion, cc-by-nc-nd)
- Informationszentrum Lebenswissenschaften (ZB MED) (submittedVersion, cc-by)
- ImmPort
- University of Chicago (cc-by)
- Funders
- National Institutes of Health (3U24GM132013-02S2)
- Morris-Singer Fund
- Topics
- Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- COVID-19 vaccine prioritization, SARS-CoV-2, serostatus, serological testing, transmission-blocking vaccine, vaccine inequity, cumulative incidence, mortality, years of life lost, naturally acquired immunity, vaccine supply
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.